Literature DB >> 24556213

A mutation in PAK3 with a dual molecular effect deregulates the RAS/MAPK pathway and drives an X-linked syndromic phenotype.

Pamela Magini1, Tommaso Pippucci1, I-Chun Tsai2, Simona Coppola3, Emilia Stellacci4, Anna Bartoletti-Stella5, Daniela Turchetti1, Claudio Graziano1, Giovanna Cenacchi6, Iria Neri7, Duccio Maria Cordelli8, Valentina Marchiani8, Rosalba Bergamaschi9, Giuseppe Gasparre1, Giovanni Neri10, Laura Mazzanti11, Annalisa Patrizi7, Emilio Franzoni8, Giovanni Romeo1, Domenico Bordo12, Marco Tartaglia4, Nicholas Katsanis2, Marco Seri13.   

Abstract

Loss-of-function mutations in PAK3 contribute to non-syndromic X-linked intellectual disability (NS-XLID) by affecting dendritic spine density and morphology. Linkage analysis in a three-generation family with affected males showing ID, agenesis of corpus callosum, cerebellar hypoplasia, microcephaly and ichthyosis, revealed a candidate disease locus in Xq21.33q24 encompassing over 280 genes. Subsequent to sequencing all coding exons of the X chromosome, we identified a single novel variant within the linkage region, affecting a conserved codon of PAK3. Biochemical studies showed that, similar to previous NS-XLID-associated lesions, the predicted amino acid substitution (Lys389Asn) abolished the kinase activity of PAK3. In addition, the introduced residue conferred a dominant-negative function to the protein that drives the syndromic phenotype. Using a combination of in vitro and in vivo studies in zebrafish embryos, we show that PAK3(N389) escapes its physiologic degradation and is able to perturb MAPK signaling via an uncontrolled kinase-independent function, which in turn leads to alterations of cerebral and craniofacial structures in vivo. Our data expand the spectrum of phenotypes associated with PAK3 mutations, characterize a novel mechanism resulting in a dual molecular effect of the same mutation with a complex PAK3 functional deregulation and provide evidence for a direct functional impact of aberrant PAK3 function on MAPK signaling.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24556213     DOI: 10.1093/hmg/ddu070

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

1.  Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.

Authors:  Tetsuya Niihori; Koki Nagai; Atsushi Fujita; Hirofumi Ohashi; Nobuhiko Okamoto; Satoshi Okada; Atsuko Harada; Hirotaka Kihara; Thomas Arbogast; Ryo Funayama; Matsuyuki Shirota; Keiko Nakayama; Taiki Abe; Shin-Ichi Inoue; I-Chun Tsai; Naomichi Matsumoto; Erica E Davis; Nicholas Katsanis; Yoko Aoki
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

2.  Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy.

Authors:  G McMichael; M N Bainbridge; E Haan; M Corbett; A Gardner; S Thompson; B W M van Bon; C L van Eyk; J Broadbent; C Reynolds; M E O'Callaghan; L S Nguyen; D L Adelson; R Russo; S Jhangiani; H Doddapaneni; D M Muzny; R A Gibbs; J Gecz; A H MacLennan
Journal:  Mol Psychiatry       Date:  2015-02-10       Impact factor: 15.992

3.  Identification of genes that promote or inhibit olfactory memory formation in Drosophila.

Authors:  Erica Walkinshaw; Yunchao Gai; Caitlin Farkas; Daniel Richter; Eric Nicholas; Krystyna Keleman; Ronald L Davis
Journal:  Genetics       Date:  2015-02-02       Impact factor: 4.562

4.  Mutations in TMEM260 Cause a Pediatric Neurodevelopmental, Cardiac, and Renal Syndrome.

Authors:  Asaf Ta-Shma; Tahir N Khan; Asaf Vivante; Jason R Willer; Pavle Matak; Chaim Jalas; Ben Pode-Shakked; Yishay Salem; Yair Anikster; Friedhelm Hildebrandt; Nicholas Katsanis; Orly Elpeleg; Erica E Davis
Journal:  Am J Hum Genet       Date:  2017-03-16       Impact factor: 11.025

5.  R106C TFG variant causes infantile neuroaxonal dystrophy "plus" syndrome.

Authors:  A Catania; R Battini; T Pippucci; R Pasquariello; M L Chiapparini; M Seri; B Garavaglia; G Zorzi; N Nardocci; D Ghezzi; V Tiranti
Journal:  Neurogenetics       Date:  2018-07-03       Impact factor: 2.660

6.  Next-Generation Sequencing Reveals Novel Mutations in X-linked Intellectual Disability.

Authors:  Babylakshmi Muthusamy; Lakshmi Dhevi N Selvan; Thong T Nguyen; Jesna Manoj; Eric W Stawiski; Bijay S Jaiswal; Weiru Wang; Remya Raja; Vedam Laxmi Ramprasad; Ravi Gupta; Sakthivel Murugan; Jayarama S Kadandale; T S Keshava Prasad; Kavita Reddy; Andrew Peterson; Akhilesh Pandey; Somasekar Seshagiri; Satish Chandra Girimaji; Harsha Gowda
Journal:  OMICS       Date:  2017-05

Review 7.  Key role of Rho GTPases in motor disorders associated with neurodevelopmental pathologies.

Authors:  David I Anderson; Evelyne Bloch-Gallego
Journal:  Mol Psychiatry       Date:  2022-08-02       Impact factor: 13.437

8.  Activating Mutations in PAK1, Encoding p21-Activated Kinase 1, Cause a Neurodevelopmental Disorder.

Authors:  Frederike L Harms; Katja Kloth; Annette Bley; Jonas Denecke; René Santer; Davor Lessel; Maja Hempel; Kerstin Kutsche
Journal:  Am J Hum Genet       Date:  2018-10-04       Impact factor: 11.025

9.  Homozygous NOTCH3 null mutation and impaired NOTCH3 signaling in recessive early-onset arteriopathy and cavitating leukoencephalopathy.

Authors:  Tommaso Pippucci; Alessandra Maresca; Pamela Magini; Giovanna Cenacchi; Vincenzo Donadio; Flavia Palombo; Valentina Papa; Alex Incensi; Giuseppe Gasparre; Maria Lucia Valentino; Carmela Preziuso; Annalinda Pisano; Michele Ragno; Rocco Liguori; Carla Giordano; Caterina Tonon; Raffaele Lodi; Antonia Parmeggiani; Valerio Carelli; Marco Seri
Journal:  EMBO Mol Med       Date:  2015-06       Impact factor: 12.137

10.  Clinical and Molecular Aspects of the Neurodevelopmental Disorder Associated with PAK3 Perturbation.

Authors:  Giulia Pascolini; Federica Gaudioso; Chiara Passarelli; Antonio Novelli; Niccolò Di Giosaffatte; Silvia Majore; Paola Grammatico
Journal:  J Mol Neurosci       Date:  2021-07-05       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.